Cargando…

Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor

BACKGROUND: Many cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC. METHODS: We used the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Guoqiao, Sundquist, Kristina, Sundquist, Jan, Försti, Asta, Hemminki, Akseli, Hemminki, Kari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643639/
https://www.ncbi.nlm.nih.gov/pubmed/32960498
http://dx.doi.org/10.1002/cam4.3454
_version_ 1783606316724387840
author Zheng, Guoqiao
Sundquist, Kristina
Sundquist, Jan
Försti, Asta
Hemminki, Akseli
Hemminki, Kari
author_facet Zheng, Guoqiao
Sundquist, Kristina
Sundquist, Jan
Försti, Asta
Hemminki, Akseli
Hemminki, Kari
author_sort Zheng, Guoqiao
collection PubMed
description BACKGROUND: Many cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC. METHODS: We used the Swedish Cancer Registry (1990‐2015) to select 13 male and 14 female first primary cancers (FPCs) that are known to be related to immune suppression. We assessed relative risks (RRs) for any of these as concordant (same first and second cancer) and discordant FPC‐SPC pairs. Hierarchical clustering of significant RRs was performed for cancers as FPC and SPC. RESULTS: Concordant risks for SPCs were excessive in men and women for nasal (RRs 59.3 for men and 150.6 for women), tongue/mouth (51.7 and 100.8), and lip (32.4 and 61.2) cancers. Heatmaps showed that some cancers, such as skin cancer, tongue/mouth cancers, and non‐Hodgkin lymphoma had multiple bidirectional associations as FPC and SPC. Nasal cancer and chronic lymphocytic leukemia had associations mainly as FPC while liver and kidney cancers showed most associations as SPC. CONCLUSIONS: Immune dysfunction may be a plausible contributing factor for most of the associations, which calls for experimental verification.
format Online
Article
Text
id pubmed-7643639
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76436392020-11-13 Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor Zheng, Guoqiao Sundquist, Kristina Sundquist, Jan Försti, Asta Hemminki, Akseli Hemminki, Kari Cancer Med Cancer Prevention BACKGROUND: Many cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC. METHODS: We used the Swedish Cancer Registry (1990‐2015) to select 13 male and 14 female first primary cancers (FPCs) that are known to be related to immune suppression. We assessed relative risks (RRs) for any of these as concordant (same first and second cancer) and discordant FPC‐SPC pairs. Hierarchical clustering of significant RRs was performed for cancers as FPC and SPC. RESULTS: Concordant risks for SPCs were excessive in men and women for nasal (RRs 59.3 for men and 150.6 for women), tongue/mouth (51.7 and 100.8), and lip (32.4 and 61.2) cancers. Heatmaps showed that some cancers, such as skin cancer, tongue/mouth cancers, and non‐Hodgkin lymphoma had multiple bidirectional associations as FPC and SPC. Nasal cancer and chronic lymphocytic leukemia had associations mainly as FPC while liver and kidney cancers showed most associations as SPC. CONCLUSIONS: Immune dysfunction may be a plausible contributing factor for most of the associations, which calls for experimental verification. John Wiley and Sons Inc. 2020-09-22 /pmc/articles/PMC7643639/ /pubmed/32960498 http://dx.doi.org/10.1002/cam4.3454 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Prevention
Zheng, Guoqiao
Sundquist, Kristina
Sundquist, Jan
Försti, Asta
Hemminki, Akseli
Hemminki, Kari
Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
title Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
title_full Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
title_fullStr Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
title_full_unstemmed Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
title_short Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
title_sort rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
topic Cancer Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643639/
https://www.ncbi.nlm.nih.gov/pubmed/32960498
http://dx.doi.org/10.1002/cam4.3454
work_keys_str_mv AT zhengguoqiao ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor
AT sundquistkristina ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor
AT sundquistjan ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor
AT forstiasta ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor
AT hemminkiakseli ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor
AT hemminkikari ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor